DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Degarelix
Degarelix
Personalized ADT
Degarelix for Treating Advanced Hormone- Dependent Prostate Cancer
Degarelix Acetate (Firmagon) Reference Number: PA.CP.PHAR.170 Effective Date: 01/18 Last Review Date: 10/18 Revision Log
Follicular and Endocrine Profiles Associated with Different Gnrh
Gnrh Antagonists Have Direct Inhibitory Effects on Castration-Resistant Prostate
214621Orig1s000
LHRH Analogues and Degarelix for Treatment of Prostate Cancer – Sorted by Drug
Firmagon®) SMC No
Gonadotropin-Releasing Hormone Antagonists Versus Standard Androgen Suppression Therapy for Advanced Prostate Cancer a Systematic Review with Meta-Analysis
Elagolix for Treating Endometriosis
Scottish Medicines Consortium
Firmagon, INN-Degarelix
Degarelix DTC Summary
Lupron Depot, Lupron Depot-PED, Firmagon, Supprelin LA, Synarel
Elagolix) Tablets
FIRMAGON® Canadian Product Monograph
New Considerations for ADT in Advanced Prostate Cancer and the Emerging Role of Gnrh Antagonists
Australian Public Assessment Report for Degarelix
Top View
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
FIRMAGON® (Degarelix for Injection)
Company Corporate Presentation
Gonadotropin Releasing Hormone Analogs (Gnrh)
Gnrh Antagonists Have Direct Inhibitory Effects on Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression Vito Cucchiara1, Joy C
Relugolix (Orgovyx™) EOCCO POLICY
Luteinizing Hormone-Releasing Hormone Antagonists
WO 2015/052204 Al Llll II II 11III II
Management of Infertility Appendixes
Degarelix (Firmagon®) Vs Leuprolide (Lupron Depot®) in Patients with Advanced Prostate Cancer: Further Analysis from a Phase Iii Pivotal Trial
Degarelix for Injection Label
FIRMAGON® Fact Sheet Degarelix
An Update on the Use of Degarelix in the Treatment of Advanced Hormone-Dependent Prostate Cancer
Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
Phase 3 HERO Study Design: Evaluation of the Safety and Efficacy of Relugolix, a Novel Oral Gnrh Receptor Antagonist, in Men with Advanced Prostate Cancer
Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men with Pedophilic Disorder a Randomized Clinical Trial
Gnrh Antagonist Treatment of Malignant Adrenocortical Tumors
214621Orig1s000
What to Expect from Your Treatment
Degarelix Acetate (Firmagon®)
Degarelix Acetate (Firmagon) Reference Number: ERX.SPMN.70 Effective Date: 07/16 Last Review Date: 06/16 Revision Log
Degarelix and Its Therapeutic Potential in the Treatment of Prostate Cancer
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer
GONADOTROPIN-RELEASING HORMONES Firmagon (Degarelix
A Degarelix Trial in Patients with Prostate Cancer Purpose
Degarelix Subcutaneous Injection (Firmagon )
Gnrh Antagonists
Hormone Therapy
Elagolix for Treating Endometriosis
A Gonadotropin-Releasing Hormone Antagonist Reduces Serum Adrenal
Publication Agenda CHMP 07-10 December 2020
Gnrh Modulators TCO 02.2019
New 0Ral Gonadotropin-Releasing Hormone (Gnrh) Antagonist
X FACT SHEET
Medication Prior Authorization Form
Comparative Clinical Effectiveness of Elagolix for Endometriosis : Research Protocol Background, Objectives, and Research Questions
Ryeqo, INN: Relugolix / Estradiol / Norethisterone Acetate